BTG plc’s (BTG) “Buy” Rating Reaffirmed at Deutsche Bank AG
Deutsche Bank AG reiterated their buy rating on shares of BTG plc (LON:BTG) in a research note published on Wednesday. They currently have a GBX 865 ($10.81) price objective on the stock, up from their prior price objective of GBX 850 ($10.62).
BTG has been the subject of a number of other reports. JPMorgan Chase & Co. restated a neutral rating on shares of BTG plc in a research note on Friday, September 9th. Numis Securities Ltd upgraded BTG plc to a buy rating and set a GBX 900 ($11.24) price target for the company in a research note on Monday, October 17th. Royal Bank Of Canada downgraded BTG plc to a sector performer rating and decreased their price target for the company from GBX 910 ($11.37) to GBX 790 ($9.87) in a research note on Tuesday, November 1st. Finally, Stifel Nicolaus upgraded BTG plc to a buy rating and raised their price target for the company from GBX 640 ($8.00) to GBX 725 ($9.06) in a research note on Thursday, November 3rd. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of GBX 820 ($10.24).
BTG plc (LON:BTG) traded up 0.49% during mid-day trading on Wednesday, hitting GBX 619.00. The stock had a trading volume of 962,885 shares. BTG plc has a one year low of GBX 554.97 and a one year high of GBX 739.50. The stock’s 50 day moving average price is GBX 661.45 and its 200 day moving average price is GBX 649.86. The firm’s market capitalization is GBX 2383.64 billion.
BTG plc Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Stock Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related stocks with our FREE daily email newsletter.